Discovery signals new treatment for those at high risk of breast and ovarian cancer

March 27, 2014

Cancer researchers at Queen's University Belfast have made a breakthrough which could signal new treatments for women at high risk of breast and ovarian cancer.

Currently around one in 1,000 in the UK carry what is known as a BRCA1 mutation - the same condition that prompted well-known actress Angelina Jolie to undergo a double mastectomy. They have up to an 85 per cent risk of developing breast cancer, and up to 40 per cent risk of developing ovarian cancer, in their lifetimes.

Until now, preventive surgery - mastectomy (breasts) and oophorectomy (ovaries) - has been the only way of reducing the risk of developing both types of cancers.

The new discovery by researchers in Queen's Centre for Cancer Research and Cell Biology (CCRCB) may mean women affected with BRCA1 could use drugs, which are already available, to reduce their risk of developing the disease, rather than undergo irreversible surgery.

In turn, such treatments would open up the possibility of some of these women, who might otherwise have an oophorectomy, still being able to have children.

The new research by Dr Kienan Savage and Professor Paul Harkin at CCRCB proves there is a direct link between high levels of oestrogen and DNA damage, which causes cancer, in the breasts and ovaries.

Specifically, the scientists discovered that the cells of women with the BRCA1 mutation cannot effectively fight the very high levels of oestrogen that exist in all women's breasts and ovaries, leaving them vulnerable to DNA damage.

While this link between oestrogen, breast/ovarian cancer and BRCA1 mutation has been suspected by the scientific community for years, it has not been proven until now.

Dr Kienan Savage, from the CCRCB, and who led the research, said: "This discovery is very significant in the management of women with the BRCA1 gene mutation. It's the first really credible evidence that oestrogen is driving cancer in women with a BRCA1 gene mutation. Because of this discovery, we now have the opportunity to propose an alternative treatment to surgery. It also opens up the possibility of pausing treatment for a period in order for women to have children, if desired.

"What also makes this exciting is that there are drugs already on the market which turn off oestrogen production. In theory, we could use these drugs to chemically reduce oestrogen production in women which could negate the need for irreversible surgery."

The Queen's-led research, which has been ongoing for four years, was carried out with funding from Cancer Focus NI and Cancer Research UK. It is carried in the latest edition of the prestigious USA-based journal Cancer Research.

Professor David Waugh, Director of the Centre for Cancer Research and Cell Biology at Queen's, said: "This breakthrough by researchers at CCRCB is great news for women with the BRCA1 gene and the community as a whole. It is pivotal in that it reveals more about the mechanisms behind breast and .

"This work of Dr Kienan Savage and Professor Paul Harkin is further example of the world-leading research being undertaken at Queen's which continues to advance knowledge and change lives."

Roisin Foster, Chief Executive, Cancer Focus Northern Ireland, said: "Cancer Focus is delighted to fund this ground-breaking research into breast , which has the potential in the forseeable future to benefit women all over the world. We are only able to support this vital work because of the generosity of our local community."

The researchers are currently seeking funding to launch clinical trials and hope to do so within 12 months. It is envisaged that, in the first instance, a small control trial will be carried out using a combination of two drugs on 12 women for a period of three months, using biopsy, blood and urine samples to track DNA damage.

Explore further: Study ties breast gene to high-risk uterine cancer

Related Stories

Study ties breast gene to high-risk uterine cancer

March 24, 2014
Women with a faulty breast cancer gene might face a greater chance of rare but deadly uterine tumors despite having their ovaries removed to lower their main cancer risks, doctors are reporting.

Preventive oophorectomy reduces risk of death by 77 percent for women with BRCA mutation

February 25, 2014
Women who carry a BRCA gene mutation and opt for a preventive oophorectomy, or ovary removal surgery, have a 77 per cent lower risk of death than those who do not, according to a new study led by Women's College Hospital's ...

Women with breast cancer gene mutation more likely to survive cancer after double mastectomy

February 11, 2014
Women who carry a mutation on the BRCA breast cancer gene - and are diagnosed with early stage breast cancer - are significantly less likely to die if they undergo a double mastectomy than those who have only one breast removed, ...

Research backs risk-reduction surgery for ovarian cancer

December 17, 2013
A study by Manchester scientists backs preventative surgery to improve survival for women who are at greater risk of getting ovarian cancer and suggests it appears helpful for women at risk of getting breast cancer because ...

Faster genetic testing method will likely transform care for patients with breast cancer

March 27, 2014
Faster and cheaper DNA sequencing techniques will likely improve care for patients with breast cancer but also create challenges for clinicians as they counsel patients on their treatment options. Those are among the conclusions ...

Drug offers prevention hope for women with BRCA breast cancer gene

August 6, 2013
Use of the anti-cancer drug Tamoxifen is associated with a dramatically reduced risk of developing a second breast tumour among women with a high risk gene mutation who have experienced breast cancer already, a new study ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.